MIAMI - Pulse Biosciences, Inc. (NASDAQ:PLSE), a biotech company with a market capitalization of $1.08 billion and an impressive 112% stock return over the past year, has announced promising results ...
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late ...
Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission Pulse Biosciences, Inc. (Nasdaq: PLSE), a company ...
Pulse Biosciences has appointed the company's co-chairman, Paul A. LaViolette, as its new chief executive. LaViolette replaces Burke T. Barrett, who was named president and CEO of the medical ...
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the appointment of Jon Skinner as the company’s Chief Financial Officer (CFO), effective February 3, 2025. Alongside his role as CFO, Mr. Skinner will ...
Some results have been hidden because they may be inaccessible to you